Alnylam announces publication of phase 3 study results for givosiran in the new england journal of medicine

Alnylam announces publication of envision phase 3 study results for givosiran in the new england journal of medicine.alnylam pharma - givosiran demonstrated significant reduction in rate of porphyria attacks compared with placebo in patients with ahp.alnylam pharma - improvements in number of secondary endpoints including reductions in urinary ala & pbg levels, days of intravenous hemin use.alnylam pharmaceuticals - in all patients with ahp, mean aar was significantly reduced by 73% relative to placebo.alnylam pharma - patients treated with givosiran reported favorable effects on exploratory endpoints related to use of analgesics, overall health status.
ALNY Ratings Summary
ALNY Quant Ranking